Technology ID
TAB-4568

Astrocyte Differentiation of Neural Stem Cells with StemPro Embryonic Stem Cell Serum Free Medium for Research and Potential Therapeutic Use

E-Numbers
E-612-2013-0
Lead Inventor
Malik, Nasir (National Institute of Neurological Disorders and Stroke)
Co-Inventors
Rao, Mahendra (New York Stem Cell Foundation)
Zeng, Xianmin (Buck Institute for Research on Aging)
Applications
Research Materials
Therapeutic Areas
Neurology
Development Stages
Pre-Clinical (in vitro)
Research Products
Human Cell Lines
Lead IC
NIAMS

This technology includes an innovative method for differentiating astrocytes from neural stem cells (NSCs). The process involves using Life Technologies StemPro embryonic stem cell serum-free medium to initially guide NSCs towards a neuronal lineage. Over a period of 28-35 days, as the cells are continually passaged, neurons gradually die off, leading to the proliferation of astrocytes. By the end of this differentiation protocol, approximately 70% of the cells exhibit markers characteristic of mature astrocytes, specifically GFAP. Additionally, this method allows for the astrocytes to be frozen at early stages and later thawed to continue their differentiation into the astrocyte lineage. This technology stands out from previous methods by significantly enhancing the efficiency and speed of astrocyte derivation. The potential applications of this technology are extensive, including facilitating research into astrocyte development mechanisms and providing a scalable way to produce astrocytes for potential clinical applications in cellular replacement therapies for brain and spinal cord injuries.

Commercial Applications
The technology holds promise for advancing research in astrocyte development and could be pivotal in cellular replacement therapies for treating brain and spinal cord injuries.

Competitive Advantages
This astrocyte differentiation technology offers a competitive advantage by enabling the efficient and rapid generation of mature astrocytes, surpassing previous methods in both speed and efficacy.
Licensing Contact:
Knezevic, Vladimir
vlado.knezevic@nih.gov